Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about BeiGene, Ltd.
BeiGene, Ltd. News
Jun 4, 2025 - seekingalpha.com
BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
Jun 2, 2025 - businesswire.com
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
May 31, 2025 - businesswire.com
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
May 27, 2025 - businesswire.com
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
BeiGene, Ltd. Quantitative Score

About BeiGene, Ltd.
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
BeiGene, Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
BeiGene, Ltd. Financials
Table Compare
Compare ONC metrics with: | |||
---|---|---|---|
Earnings & Growth | ONC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ONC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ONC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ONC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
BeiGene, Ltd. Income
BeiGene, Ltd. Balance Sheet
BeiGene, Ltd. Cash Flow
BeiGene, Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Sell |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
BeiGene, Ltd. Executives
Name | Role |
---|---|
Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder |
Mr. John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer |
Mr. Aaron Rosenberg | Chief Financial Officer |
Dr. Xiaobin Wu Ph.D. | President, Chief Operating Officer & GM of China |
Mr. Wang Lai Ph.D. | Global Head of R&D |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | 1963 | 4.25M | |
Mr. John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer | Male | 1968 | 2.84M |
Mr. Aaron Rosenberg | Chief Financial Officer | Male | 1977 | 1.93M |
Dr. Xiaobin Wu Ph.D. | President, Chief Operating Officer & GM of China | 1963 | 1.84M | |
Mr. Wang Lai Ph.D. | Global Head of R&D | Male | 1978 | 1.2M |
BeiGene, Ltd. Insider Trades
Date | 21 May |
Name | BAKER BROS. ADVISORS LP |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 21970 |
Date | 21 May |
Name | BAKER BROS. ADVISORS LP |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 21970 |
Date | 21 May |
Name | BAKER BROS. ADVISORS LP |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 45500 |
Date | 28 Feb |
Name | BAKER BROS. ADVISORS LP |
Role | Director |
Transaction | Disposed |
Type | S-Sale |
Shares | 60851 |
Date | 28 Feb |
Name | BAKER BROS. ADVISORS LP |
Role | Director |
Transaction | Disposed |
Type | S-Sale |
Shares | 671976 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
21 May | BAKER BROS. ADVISORS LP | Director | Acquired | A-Award | 21970 |
21 May | BAKER BROS. ADVISORS LP | Director | Acquired | A-Award | 21970 |
21 May | BAKER BROS. ADVISORS LP | Director | Acquired | A-Award | 45500 |
28 Feb | BAKER BROS. ADVISORS LP | Director | Disposed | S-Sale | 60851 |
28 Feb | BAKER BROS. ADVISORS LP | Director | Disposed | S-Sale | 671976 |